Michael Dougherty was appointed a member of Idera’s Board of Directors in April, 2019. Mr. Dougherty most recently served as the executive chairman of Celator Pharmaceuticals, Inc. from August 2015 until its acquisition by Jazz Pharmaceuticals in July 2016. Mr. Dougherty served as a director of Celator from July 2013 to July 2016. Mr. Dougherty previously served in a variety of senior positions, including chief executive officer of Kalidex Pharmaceuticals, Inc., chief executive officer of Adolor Corporation, chief operating officer of Genomics Collaborative, Inc., chief executive officer of Genaera Corporation, and chief financial officer at Centocor, Inc. He currently serves on the board of directors of Marinus Pharmaceuticals, Inc. and Trevena, Inc., both publicly traded life sciences organizations. Mr. Dougherty also served on the board of directors of Foundation Medicine, Inc., Aviragen Therapeutics, Inc., Cempra, Inc., and ViroPharma Incorporated from 2004 until its acquisition by Shire in 2014.
Mr. Dougherty received a Bachelor of Science in Accounting from Villanova University.